<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006054</url>
  </required_header>
  <id_info>
    <org_study_id>2019040111</org_study_id>
    <nct_id>NCT04006054</nct_id>
  </id_info>
  <brief_title>Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury</brief_title>
  <official_title>Cerebral Protection of Dexmedetomidine Against Paroxysmal Sympathetic Overexcited in Patients With Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine&#xD;
      release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paroxysmal sympathetic hyperactivity (PSH) is a syndrome typically recognized in patients&#xD;
      suffering from traumatic brain injury, characterized by paroxysmal increases in sympathetic&#xD;
      activity such as elevated heart rate, increased blood pressure and respiratory rate, high&#xD;
      temperature, excessive sweating and abnormal motor (posturing) activity.&#xD;
&#xD;
      This prospective study will include patients with traumatic brain injury,who will be divided&#xD;
      into two groups, evaluated by the Paroxysmal Sympathetic Hyperactivity-Assessment Measure&#xD;
      (PSH-AM). Patients will also be evaluated with head CT.&#xD;
&#xD;
      The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine&#xD;
      release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>At admission (baseline)</time_frame>
    <description>Epinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>24 hours after injury</time_frame>
    <description>Epinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>48 hours after injury</time_frame>
    <description>Epinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>72 hours after injury</time_frame>
    <description>Epinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>At admission (baseline)</time_frame>
    <description>Norepinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>24 hours after injury</time_frame>
    <description>Norepinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>48 hours after injury</time_frame>
    <description>Norepinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>72 hours after injury</time_frame>
    <description>Norepinephrine is a hormone secreted by the body.When the patient suffers brain injury, the concentration of Epinephrine will increase significantly.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .</description>
    <arm_group_label>Dexmedetomidine treatment group</arm_group_label>
    <other_name>DG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .</description>
    <arm_group_label>Midazolam treatment group</arm_group_label>
    <other_name>MG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-70 years&#xD;
&#xD;
          2. Moderate or severe traumatic brain injury&#xD;
&#xD;
          3. GCS≤12&#xD;
&#xD;
          4. Diagnosed by CT&#xD;
&#xD;
          5. No catecholamines (such as dopamine, adrenaline, norepinephrine) have been used before&#xD;
             admission&#xD;
&#xD;
          6. Have a clear history of head trauma&#xD;
&#xD;
          7. Non-open traumatic brain injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe liver dysfunction (Child-Pugh B or C)&#xD;
&#xD;
          2. Severe renal dysfunction (serum creatinine &gt; 445 mmol / L or blood urea nitrogen &gt; 20&#xD;
             mmol / L)&#xD;
&#xD;
          3. Hemodynamic instability when entering the ICU (heart rate &lt;50 beats / min or&#xD;
             hypotension, SBP &lt;90mmHg or MAP &lt;65mmHg)&#xD;
&#xD;
          4. Deaths within 72 hours after entering the ICU&#xD;
&#xD;
          5. Severe multiple injuries (ISS≥25 points)&#xD;
&#xD;
          6. Have central nervous system diseases (such as hypoxic ischemic encephalopathy, stroke,&#xD;
             brain tumors, etc.)&#xD;
&#xD;
          7. Allergic to dexmedetomidine or midazolam&#xD;
&#xD;
          8. Observed with the results of disease interference test (such as pheochromocytoma,&#xD;
             etc.)&#xD;
&#xD;
          9. In pregnancy or lactation&#xD;
&#xD;
         10. Receiving hypothermia treatment&#xD;
&#xD;
         11. Are participating in other drug research or clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Chen, Doctor</last_name>
    <phone>13517315332</phone>
    <email>21806497@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfang Liu, Doctor</last_name>
      <phone>13975800826</phone>
      <email>1427822007@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>June 30, 2019</last_update_submitted>
  <last_update_submitted_qc>June 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

